Glucose Health (GLUC) Return on Equity ROE from the third quarter 2017 to third quarter 2016 and annually, average high and low, overall ranking from Sep 30 2017 to Sep 30 2016 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Glucose Health, Inc.  (GLUC)

Glucose Health's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Glucose Health in the third quarter 2017?
Due to the lack of equity, it was not possible to calculate Glucose Health, Inc.'s return on equity (ROE) in its third quarter 2017

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2017)
III. Quarter		 (Jun 30 2017)
II. Quarter		 (Mar 31 2017)
I. Quarter		 (Dec 31 2016)
IV. Quarter		 (Sep 30 2016)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 0 0 0 0 0
Return On Equity (TTM) - - - - -
GLUC's Total Ranking # # # # #
Equity (TTM) in Millions 0 0 -1 0 0
Seq. Equity Change - - - - -
Seq. Net Income Change -61.9 % - - - -

Back to GLUC Management Effectiveness >> GLUC's 5 Years Annual ROE >> Compare GLUC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





GLUC Annual Return On Equity (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014		 (Dec 31 2013)
2013		 (Dec 31 2012)
2012
Total Equity in Millions 0 0 0 0 0
Y / Y Equity Change - - - - -
Net Income in Millions 0 0 -1 -1 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -1824.77 %

Back to GLUC Management Effectiveness >> GLUC's 5 Years Annual ROE >> Compare GLUC ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GLUC's' Return on Equity at Yahoo Finance
GLUC's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GLUC's Competitors
Subscribers only: Roe for Glucose Health's Suppliers
Subscribers only: Return On Equity for GLUC's Customers




Companies with similar Return On Equity at Sep 30 2017, within Healthcare Sector ROE
Zoetis Inc   54.27 %
Masimo Corp  52.60 %
Gilead Sciences Inc   52.26 %
Phibro Animal Health Corporation  49.65 %
Ligand Pharmaceuticals Incorporated  48.67 %
3m Company  48.64 %
Sonoma Pharmaceuticals Inc   44.70 %
Opiant Pharmaceuticals Inc   42.36 %
Pro dex Inc   41.88 %
Jrsis Health Care Corp  40.60 %
Luna Innovations Inc  38.02 %
Psychemedics Corporation  37.32 %
Biodelivery Sciences International Inc   33.82 %
Bausch Health Companies Inc   33.64 %
Bard C R Inc  31.67 %
Oramed Pharmaceuticals Inc  30.27 %
Biogen Inc   29.02 %
Encompass Health Corporation  28.87 %
Illumina Inc   28.01 %
Bristol myers Squibb Company  27.73 %
Tivity Health Inc   27.62 %
Ethema Health Corporation   27.55 %
Remedent Inc   27.21 %
Supernus Pharmaceuticals inc   26.37 %
Amgen Inc   26.28 %
United Therapeutics Corporation  26.24 %
Edwards Lifesciences Corporation  25.99 %
Nrc Health  25.68 %
Align Technology inc   25.00 %
Regeneron Pharmaceuticals Inc   24.78 %

Date modified: 2026-09-08T15:09:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.